Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 12/20 | 0.48 |
| ▸ | FLT1 | P17948 | 2/20 | 0.48 |
| ▸ | FLT4 | P35916 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.45 |
| ▸ | TNNI3K | Q59H18 | 6/20 | 0.45 |
| ▸ | BRAF | P15056 | 5/20 | 0.45 |
| ▸ | RET | P07949 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | MAP2K7 | O14733 | 2/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13408258 | 0.92 | KDR (0.51) | KDRFLT1FLT4GAAMAPK14 | |
| SCHEMBL3597680 | 0.92 | KDR (0.49) | KDRFLT1FLT4GAAMAPK14 | |
| SCHEMBL3589751 | 0.81 | KDR (0.53) | KDRMAPK14TNNI3KBRAFRET | |
| SCHEMBL3596312 | 0.80 | NPC1 (0.50) | KDRRAB9ACDK8 | |
| SCHEMBL3589289 | 0.80 | BRAF (0.60) | KDRMAPK14TNNI3KBRAFRET | |
| SCHEMBL13408255 | 0.79 | BRAF (0.49) | KDRMAPK14TNNI3KBRAFRET | |
| SCHEMBL2433502 | 0.75 | KDR (0.80) | KDRFLT1FLT4MAPK14TNNI3K | |
| SCHEMBL3588092 | 0.71 | NPC1 (0.51) | KDRGAAMAPK14TNNI3KBRAF | |
| SCHEMBL3601549 | 0.71 | KDR (0.54) | KDRMAPK14TNNI3KBRAFRET | |
| SCHEMBL13408250 | 0.71 | KDR (0.65) | KDRFLT1FLT4MAPK14TNNI3K |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1643991-B1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2014-03-12 | — | — | EP | disclosed |
| US-7691870-B2 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2010-04-06 | — | — | US | disclosed |
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | MERCK PATENT GMBH (DE) | 2007-04-26 | — | — | US | disclosed |
| EP-1643991-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005004863-A1 | BENZIMIDAZOLE CARBOXAMIDES AS RAF KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093532-A1 | Benzimidazole carboxamides as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 843/4885FLT1 627/4885FLT4 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.